Duchenne muscular dystrophy (DMD) is a congenital X-linked muscular dystrophy, and cardiomyopathy typically develops in the second decade of life. In those patients with severe heart failure, the use of mechanical circulatory support is considered one of the treatment options, however, the decision to implant the assist device should be made after gauging the inherent risks and potential benefits. Transcatheter mitral valve repair (TMVr) is performed in adults with heart failure due to severe mitral regurgitation (MR) refractory to guideline-directed medical therapies. Data on MitraClip-based treatment (Abbott Vascular, Menlo Park, CA, USA) of young patients with cardiomyopathy-associated severe heart failure remain limited. We present the first report on the safety and effectiveness of TMVr with the MitraClip in an 18-year-old man with DMD and severe MR who was at a prohibitive risk for mitral valve surgery or left ventricular assist device therapy due to comorbidities. He was discharged without complications and, is now asymptomatic at one year after TMVr.
Learning objective: Readers will be able to:Understand the mechanism of mitral regurgitationUnderstand the less invasiveness and usefulness of this procedure.Discuss the indication of transcatheter mitral valve repair in young patients with severe heart failure.
Keywords: Functional mitral regurgitation; Heart failure; MitraClip.
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.